AU2014340114B2 - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents
Compounds for use in prevention and treatment of neurodegenerative diseases and pain Download PDFInfo
- Publication number
- AU2014340114B2 AU2014340114B2 AU2014340114A AU2014340114A AU2014340114B2 AU 2014340114 B2 AU2014340114 B2 AU 2014340114B2 AU 2014340114 A AU2014340114 A AU 2014340114A AU 2014340114 A AU2014340114 A AU 2014340114A AU 2014340114 B2 AU2014340114 B2 AU 2014340114B2
- Authority
- AU
- Australia
- Prior art keywords
- pain
- adenosine
- compound
- group
- tdp43
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894699P | 2013-10-23 | 2013-10-23 | |
| US61/894,699 | 2013-10-23 | ||
| PCT/US2014/061734 WO2015061426A1 (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014340114A1 AU2014340114A1 (en) | 2016-05-26 |
| AU2014340114B2 true AU2014340114B2 (en) | 2018-10-18 |
Family
ID=52993493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014340114A Active AU2014340114B2 (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10301348B2 (https=) |
| EP (1) | EP3060566B1 (https=) |
| JP (1) | JP6534997B2 (https=) |
| KR (1) | KR102313314B1 (https=) |
| CN (1) | CN106414456B (https=) |
| AU (1) | AU2014340114B2 (https=) |
| BR (1) | BR112016008901B1 (https=) |
| CA (1) | CA2927699C (https=) |
| IL (1) | IL245103B (https=) |
| MX (1) | MX367707B (https=) |
| RU (1) | RU2695358C2 (https=) |
| SG (1) | SG11201603063WA (https=) |
| WO (1) | WO2015061426A1 (https=) |
| ZA (1) | ZA201603118B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675293B2 (en) * | 2015-05-29 | 2020-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
| US11753432B2 (en) | 2017-01-27 | 2023-09-12 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
| EP4476235A4 (en) * | 2022-02-10 | 2026-02-18 | Academia Sinica | METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION |
| TWI910441B (zh) * | 2022-07-07 | 2026-01-01 | 中央研究院 | 治療思覺失調症之方法及用於其中之組成物 |
| CA3275345A1 (en) * | 2022-12-29 | 2024-07-04 | Academia Sinica | METHODS FOR TREATING SLEEP DISORDERS AND COMPOSITION INTENDED FOR USE THEREOF |
| TW202500138A (zh) * | 2023-03-17 | 2025-01-01 | 中央研究院 | 治療結節性硬化症或癲癇之方法及用於其中之組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012064340A1 (en) * | 2009-11-13 | 2012-05-18 | Academia Sinica | Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases |
| WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8274187A (en) | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
| US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
| SG80526A1 (en) * | 1990-09-25 | 2001-05-22 | Rhone Poulenc Rorer Int | Compounds having antihypertensive and anti- ischemic properies |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| CA2783859A1 (en) * | 2009-12-10 | 2011-06-16 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof |
| WO2013120076A1 (en) | 2012-02-09 | 2013-08-15 | Brand Bumps, LLC | Decorative detectable warning panel having improved grip |
-
2014
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/ja active Active
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/en active Active
- 2014-10-22 MX MX2016005174A patent/MX367707B/es active IP Right Grant
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/ko active Active
- 2014-10-22 CA CA2927699A patent/CA2927699C/en active Active
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/zh active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/pt active IP Right Grant
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/ru active
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/en not_active Ceased
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012064340A1 (en) * | 2009-11-13 | 2012-05-18 | Academia Sinica | Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases |
| WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015061426A1 (en) | 2015-04-30 |
| US20160264613A1 (en) | 2016-09-15 |
| NZ719740A (en) | 2021-02-26 |
| JP6534997B2 (ja) | 2019-06-26 |
| CA2927699C (en) | 2022-07-05 |
| BR112016008901B1 (pt) | 2022-08-23 |
| EP3060566A4 (en) | 2017-06-14 |
| RU2016118282A (ru) | 2017-11-28 |
| CA2927699A1 (en) | 2015-04-30 |
| CN106414456B (zh) | 2018-12-14 |
| ZA201603118B (en) | 2019-04-24 |
| MX367707B (es) | 2019-09-03 |
| IL245103B (en) | 2019-02-28 |
| RU2016118282A3 (https=) | 2018-06-18 |
| AU2014340114A1 (en) | 2016-05-26 |
| IL245103A0 (en) | 2016-06-30 |
| KR20160086852A (ko) | 2016-07-20 |
| MX2016005174A (es) | 2016-08-11 |
| EP3060566A1 (en) | 2016-08-31 |
| JP2016535019A (ja) | 2016-11-10 |
| CN106414456A (zh) | 2017-02-15 |
| US10301348B2 (en) | 2019-05-28 |
| BR112016008901A2 (pt) | 2020-05-12 |
| RU2695358C2 (ru) | 2019-07-23 |
| KR102313314B1 (ko) | 2021-10-19 |
| SG11201603063WA (en) | 2016-05-30 |
| EP3060566B1 (en) | 2018-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014340114B2 (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | |
| JP7661228B2 (ja) | オリゴヌクレオチド組成物及びその方法 | |
| AU2021230473A1 (en) | Oligonucleotide compositions and methods thereof | |
| TW201920672A (zh) | 寡核苷酸組合物及其使用方法 | |
| EP3781564A1 (en) | Compounds for the treatment of cancer | |
| TWI863999B (zh) | siRNA綴合物、其用途及使用其之方法 | |
| JP2022536085A (ja) | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 | |
| KR20240129627A (ko) | Unc13a 유전자 전사체의 조정제를 사용한 신경계 질환의 치료 | |
| JP2020537688A (ja) | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド | |
| JP2022537581A (ja) | Ppm1阻害剤およびその使用方法 | |
| AU2024338611A1 (en) | Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto | |
| TWI650328B (zh) | 用於預防及治療神經退化疾病及疼痛之化合物 | |
| TWI668007B (zh) | 用於預防及治療神經退化疾病及疼痛之化合物 | |
| RU2847121C2 (ru) | Композиции на основе олигонуклеотидов и способы, связанные с ними | |
| KR20260022373A (ko) | 변형된 unc13a 올리고뉴클레오티드 | |
| CN116528878A (zh) | 使用基因转录物调控剂治疗神经学疾病 | |
| HK40110835A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| HK40027139A (en) | Oligonucleotide compositions and methods thereof | |
| HK40056327A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |